Sign in →

Test Code SP7CC Septin-7 Antibody, Cell-Binding Assay, Spinal Fluid


Specimen Required


Only orderable as a reflex. For more information see:

-ENC2 / Encephalopathy, Autoimmune /Paraneoplastic Evaluation, Spinal Fluid

-MDC2 / Movement Disorder, Autoimmune /Paraneoplastic Evaluation, Spinal Fluid

-MAC1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

 

Container/Tube: Sterile vial

Specimen Volume: 1.5 mL


Useful For

Detecting septin-7 IgG by cell-binding assay using cerebrospinal fluid specimens

Testing Algorithm

If the indirect immunofluorescence pattern suggests septin-7, then this test and septin-7 antibody IFA titer will be performed at an additional charge.

Method Name

Only orderable as a reflex. For more information see:

-ENC2 / Encephalopathy, Autoimmune /Paraneoplastic Evaluation, Spinal Fluid

-MDC2 / Movement Disorder, Autoimmune /Paraneoplastic Evaluation, Spinal Fluid

-MAC1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

 

Cell-Binding Assay (CBA)

Reporting Name

Septin-7 CBA, CSF

Specimen Type

CSF

Specimen Minimum Volume

See Specimen Required

Specimen Stability Information

Specimen Type Temperature Time
CSF Refrigerated (preferred) 28 days
  Frozen  28 days
  Ambient  72 hours

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject

Clinical Information

Neurological phenotypes for septin-7 IgG positive patients include encephalopathy, myelopathy, encephalomyelopathy, painful myelopolyradiculopathy, and episodic ataxia. Psychiatric symptoms are also common with encephalopathic symptoms. Septin-7 IgG is also associated with cancer. Positive response to immunotherapy.

Reference Values

Only orderable as a reflex. For more information see:

-ENC2 / Encephalopathy, Autoimmune /Paraneoplastic Evaluation, Spinal Fluid

-MDC2 / Movement Disorder, Autoimmune /Paraneoplastic Evaluation, Spinal Fluid

-MAC1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

 

Negative

Interpretation

Seropositivity for septin antibodies by indirect immunofluorescence assay is consistent with a diagnosis of autoimmune disease of the central nervous system. Cell-binding assay (CBA) testing for septin-7 IgG is required to confirm the diagnosis. Seropositivity for Septin-7 IgG by CBA confirms a diagnosis of autoimmune disease of the central nervous system. A paraneoplastic cause should be considered in patients with septin-7-IgG.

Cautions

Negative results for septin-7 IgG by cell-binding assay do not exclude neurological autoimmunity or cancer.

Clinical Reference

Honorat JA, Miske R, Scharf M, et al: 416. Neuronal septin autoimmunity: Differentiated serological profiles and clinical findings. Ann Neurol. 2020 Oct;88(Suppl 25):S55. Abstract

Method Description

Patient specimen is applied to a composite slide containing transfected and nontransfected HEK-293 cells. After incubation and washing, fluorescein-conjugated goat-antihuman IgG is applied to detect the presence of patient IgG binding.(Package insert: IIFT: Neurology Mosaics, Instructions for the indirect immunofluorescence test. EUROIMMUN; FA_112d-1_A_UK_C13, 02/2019)

Day(s) Performed

Monday through Sunday

Report Available

5 to 10 days

Specimen Retention Time

28 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

86255

LOINC Code Information

Test ID Test Order Name Order LOINC Value
SP7CC Septin-7 CBA, CSF 101466-1

 

Result ID Test Result Name Result LOINC Value
615872 Septin-7 CBA, CSF 101466-1

NY State Approved

Yes